Adicet Bio (ACET) to Release Quarterly Earnings on Tuesday

Adicet Bio (NASDAQ:ACET - Get Free Report) is projected to announce its earnings results before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.

Adicet Bio (NASDAQ:ACET - Get Free Report) last released its earnings results on Thursday, March 6th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.05. On average, analysts expect Adicet Bio to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Adicet Bio Stock Up 0.9 %

Shares of Adicet Bio stock traded up $0.01 on Friday, hitting $0.78. 111,325 shares of the company's stock traded hands, compared to its average volume of 852,107. The stock has a market cap of $64.71 million, a P/E ratio of -0.46 and a beta of 1.97. The firm's 50-day moving average is $0.91 and its 200 day moving average is $1.13. Adicet Bio has a 52-week low of $0.74 and a 52-week high of $2.43.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ACET shares. StockNews.com cut Adicet Bio from a "hold" rating to a "sell" rating in a research note on Tuesday, November 19th. HC Wainwright restated a "neutral" rating on shares of Adicet Bio in a research note on Friday, March 7th. Finally, JMP Securities restated a "market perform" rating on shares of Adicet Bio in a research note on Thursday, February 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Adicet Bio has a consensus rating of "Hold" and an average target price of $7.50.

Remove Ads

About Adicet Bio

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.